{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"33.8","upperLimit":"44.2","value":"39.0"},{"groupId":"OG001","lowerLimit":"26.6","upperLimit":"36.4","value":"31.5"},{"groupId":"OG002","lowerLimit":"24.2","upperLimit":"34.0","value":"29.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"342"},{"groupId":"OG001","value":"346"},{"groupId":"OG002","value":"344"}],"units":"Participants"}],"description":"Alive at 24 months (OS24) is defined as the Kaplan-Meier estimate of OS at 24 months.","dispersionType":"95% Confidence Interval","groups":[{"description":"MEDI4736 (Durvalumab) + Tremelimumab","id":"OG000","title":"Combination Therapy"},{"description":"MEDI4736 (Durvalumab)","id":"OG001","title":"Monotherapy"},{"description":"Standard of Care Chemotherapy Treatment","id":"OG002","title":"Standard of Care"}],"paramType":"NUMBER","populationDescription":"Full analysis set (FAS) included all randomized participants analyzed on an intent-to-treat (ITT) basis.","reportingStatus":"POSTED","timeFrame":"From randomization date until death due to any cause, assessed up to 24 months or the data cut-off date (27JAN2020).","title":"Alive at 24 Months (OS24), Full Analysis Set","type":"SECONDARY","unitOfMeasure":"percentage of participants"}